quote marks icon
We have the power to heal, the passion to help, and the ability to execute.
quote marks icon
Noah Rosenberg, M.D., has served as chief medical officer of Travere Therapeutics since July 2018 and is responsible for overseeing the company’s clinical development, as well as clinical operations, pharmacokinetics, medical affairs, patient advocacy and pharmacovigilance. He brings more than 20 years of clinical and therapeutic development experience, including advancing several mid- and late-stage programs across therapeutic areas through to commercialization.
Previously, Dr. Rosenberg served as chief medical officer at Medimetriks Pharmaceuticals where he was responsible for the clinical development and medical strategy for pipeline candidates and multiple product launches. He also served as chief medical officer of Esperion Therapeutics, where he led the design, protocol implementation, execution and monitoring of innovative clinical programs. Prior to joining Esperion, Dr. Rosenberg served as the executive director and head of cardiovascular and metabolism clinical development for the Forest Research Institute, where he led the advancement of multiple late-stage clinical trials. Earlier in his career, he held leadership roles in clinical development, medical affairs and administration at Sanofi Aventis and Pfizer. Dr. Rosenberg completed his internal medicine residency at The Icahn School of Medicine at Mount Sinai Hospital and holds a medical degree from the Drexel University College of Medicine and a B.A. from Johns Hopkins University.
What is Noah L. Rosenberg's net worth?
The estimated net worth of Noah L. Rosenberg is at least $530,253.75 as of September 22nd, 2020. Dr. Rosenberg owns 29,055 shares of Travere Therapeutics stock worth more than $530,254 as of November 23rd. This net worth estimate does not reflect any other investments that Dr. Rosenberg may own. Learn More about Noah L. Rosenberg's net worth.
How do I contact Noah L. Rosenberg?
Has Noah L. Rosenberg been buying or selling shares of Travere Therapeutics?
Who are Travere Therapeutics' active insiders?
Are insiders buying or selling shares of Travere Therapeutics?
During the last year, insiders at the sold shares 19 times. They sold a total of 160,806 shares worth more than $1,943,699.05. The most recent insider tranaction occured on October, 4th when Director Gary A Lyons sold 40,000 shares worth more than $589,200.00. Insiders at Travere Therapeutics own 3.8% of the company.
Learn More about insider trades at Travere Therapeutics. Information on this page was last updated on 10/4/2024.
